Condition: Metastatic Non-small Cell Lung Cancer (NSCLC) · Metastatic Cutaneous Melanoma · Sponsor: EuroCityClinic LLC
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.
This description comes directly from the study's public registry record.
Sergey V. Orlov, Professor · +79811957915 · orloff-sv@mail.ru
Aram A. Musaelyan, PhD · +79990263455 · a.musaelyan8@gmail.com
Always discuss trial participation with your own doctor first.
| EuroCityClinic LLC | Saint Petersburg, Sankt-Peterburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07130032